Results(4699)
A Non-Interventional Study (NIS) PASS to characterize secondary malignancies of T-cell origin following tisagenlecleucel therapy (CCTL019B2402)
Australia
Austria
Brazil
Canada
Czechia
France
Germany
Hong Kong
Israel
Italy
Japan
Korea, Republic of
Netherlands
Poland
Russian Federation
Saudi Arabia
Singapore
Spain
Switzerland
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS1000000749
First published:
08/04/2026
Study
Ongoing
A regulatory requirement non-interventional study to monitor the safety and effectiveness of Spesolimab in Korean patients with flares with generalized pustular psoriasis
Korea, Republic of
EU PAS number:
EUPAS1000000278
First published:
08/04/2026
Study
Discontinued
An Observational Registry-Based Study to Evaluate the Long-Term Safety of Tofersen in People With SOD1-ALS
United States
EU PAS number:
EUPAS1000000365
First published:
08/04/2026
Study
Ongoing
DARWIN EU® - Feasibility of studies on early (pre-symptomatic) stages of type 1 diabetes mellitus in the DARWIN EU® network
Denmark
Finland
France
Hungary
Netherlands
Spain
EU PAS number:
EUPAS1000000756
First published:
08/04/2026
Study
Finalised
DARWIN EU® - Population demographics and disease frequency across the DARWIN EU® network
Belgium
Croatia
Estonia
France
Germany
Greece
Hungary
Netherlands
Norway
Portugal
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000962
First published:
08/04/2026
Study
Ongoing
INFARMED – National Authority of Medicines and Health Products, I.P.
Portugal
First published:
08/04/2026
Institution
EEA National Competent authority
Healthcare payer
Regulatory Authority
ENCePP partner
CROSSROADS-2: Clinical Characteristics, Treatment Patterns, and Treatment Outcomes Among Users of Tezspire: An Electronic Medical Record (EMR) study (20220066)
United States
EU PAS number:
EUPAS1000000053
First published:
08/04/2026
Study
Ongoing
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Certified Prescribers to Assess Understanding of the Risks with the BKEMV™ Risk Evaluation and Mitigation Strategy (REMS) (20240216)
United States
EU PAS number:
EUPAS1000000367
First published:
08/04/2026
Study
Ongoing
General Use-results Survey of IMDELLTRA in Patients with Small Cell Lung Cancer Progressed after Cancer Chemotherapy (20230313)
Japan
EU PAS number:
EUPAS1000000817
First published:
08/04/2026
Study
Ongoing
Investigating the effect of the 13-valent pneumococcal conjugate vaccine on major adverse cardiovascular events among Medicare enrollees aged ≥65 years in the United States
United States
EU PAS number:
EUPAS1000000520
First published:
08/04/2026
Study
Ongoing
COPD, Bronchiectasis and Asthma Longitudinal Trends
France
Germany
Japan
United States
EU PAS number:
EUPAS1000000925
First published:
08/04/2026
Study
Planned
Real-world Comparative Effectiveness of Evolocumab Versus Ezetimibe in Reducing the Risk of Fatal and Nonfatal Myocardial Infarction (20240027)
United States
EU PAS number:
EUPAS1000000522
First published:
07/04/2026
Study
Ongoing
MS700568_0151: An observational, multicenter, prospective, phase IV study evaluating cladribine tablets’ effects on PROs and their correlation with clinical and biometric parameters using Health Technology in subjects with highly-active RMS at their first switch (CLADFIT-MS)
Italy
EU PAS number:
EUPAS43893
First published:
01/04/2026
Study
Finalised
Linkage of Swedish national registers for psychiatric research
Birth registry
Death registry
Hospital inpatient records
Hospital outpatient visit records
Pharmacy dispensing records
Population registry
Sweden
First published:
01/04/2026
Data source
Human
Record completeness: 67%
MS100070_0031: Non-interventional cohort registry study to assess characteristics and management of patients with Merkel Cell Carcinoma in Germany (MCC-TRIM)
Germany
EU PAS number:
EUPAS25338
First published:
01/04/2026
Study
Finalised
Fezolinetant Experience for the Treatment of Vasomotor Symptoms Associated with Menopause Among Women in a German Real-life Setting
Germany
EU PAS number:
EUPAS1000000132
First published:
01/04/2026
Study
Ongoing
Prospective Observational Non-interventional Study to Describe Characteristics and Management of Patients With Giant Cell Tumor of Bone Treated With XGEVA and Its Use in Routine Clinical Practice in France (20150360)
France
EU PAS number:
EUPAS21542
First published:
01/04/2026
Study
Finalised
Optimum Patient Care Research Database
Other
Primary care medical records
United Kingdom
United Kingdom (Northern Ireland)
First published:
31/03/2026
Data source
Human
Record completeness: 100%
Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
Disease registry
Primary care medical records
United Kingdom
First published:
31/03/2026
Data source
Human
Record completeness: 98%
Drug-Drug Interactions Between ADHD and Cardiometabolic Medications: a Pharmacovigilance Study
Australia
Denmark
Sweden
United States
EU PAS number:
EUPAS1000000761
First published:
31/03/2026
Study
Planned
DARWIN EU® - Characterisation of acute renal outcomes and diabetic complications among patients with concomitant use of metformin and iodinated contrast agents
Denmark
Finland
Spain
United Kingdom
EU PAS number:
EUPAS1000000662
First published:
31/03/2026
Study
Finalised
ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
Finland
France
Italy
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000246
First published:
31/03/2026
Study
Ongoing
TAK-669-4018: A Survey Among Patients, Caregivers and Home Infusion Nurses Based in the European Union to Assess Their Awareness and Understanding of Educational Materials Supporting VPRIV® Infusion at Home
Austria
Belgium
Denmark
Finland
France
Germany
Ireland
Italy
Netherlands
Spain
EU PAS number:
EUPAS49598
First published:
31/03/2026
Study
Planned
DARWIN EU® - Characterising the incidence and presentation of myocarditis and/or pericarditis in Europe
Denmark
Finland
Germany
Netherlands
Norway
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000967
First published:
31/03/2026
Study
Ongoing
MS700568_0199: Prospective Observational Study Aimed at Evaluating Treatment Satisfaction and Effectiveness in Patients with Relapsing Multiple Sclerosis Starting CLADRibinE TAbLets (CLADREAL)
Italy
EU PAS number:
EUPAS49334
First published:
31/03/2026
Study
Ongoing
Real-world use of enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and immunotherapy: a multicenter, retrospective, non-interventional study in France
France
EU PAS number:
EUPAS105591
First published:
31/03/2026
Study
Finalised
Centre for Health Protection (RIVM-GZB), National Institute for Public Health & Environment
Netherlands
First published:
30/03/2026
Institution
EU Institution/Body/Agency
Laboratory/Research/Testing facility
ENCePP partner
Leibniz Institute for Prevention Research and Epidemiology - BIPS
Germany
First published:
30/03/2026
Institution
Not-for-profit
ENCePP partner
EMR200136_593: A Study Assessing the U.S. Post-Marketing Safety Profile of Rebif® in comparison with its U.S. Prescribing Information
United States
EU PAS number:
EUPAS7290
First published:
30/03/2026
Study
Finalised
EMR200084_512: Risk of lactic acidosis with metformin use in type 2 diabetes mellitus with renal impairment: retrospective cohort study
United Kingdom
EU PAS number:
EUPAS8658
First published:
30/03/2026
Study
Finalised
Real-World Treatment Patterns and Clinical Outcomes of BRAF V600-Mutant Metastatic Melanoma Patients Treated at Academic Oncology Centers in the United States
United States
EU PAS number:
EUPAS1000000307
First published:
30/03/2026
Study
Planned
EMR200101_502: Incidence and pattern description of gastrointestinal, skin, genital, corneal, and mucosal erosions, ulcerations, perforations, haemorrhages, fistulas, abscesses, delayed wound healing and death among patients treated with nicorandil with and without diverticular disease
United Kingdom
EU PAS number:
EUPAS13205
First published:
30/03/2026
Study
Finalised
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Certified Prescribers to Assess Understanding of the Risks with the Prolia Risk Evaluation and Mitigation of Strategy (REMS) (20240121)
United States
EU PAS number:
EUPAS1000000393
First published:
30/03/2026
Study
Ongoing
Population-based retrospective nested case-control study evaluating effectiveness of GARDASIL™ /GARDASIL™9 against adult-onset recurrent respiratory papillomatosis (AoRRP) in Sweden, Denmark, and Norway (V503-088)
Denmark
Norway
Sweden
EU PAS number:
EUPAS48452
First published:
30/03/2026
Study
Ongoing
Effect of Glucagon-Like Peptide-1 Receptor Agonists on the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy Among Older Adults with Type 2 Diabetes: A US. Medicare Active-Comparator New-User Cohort Study
United States
EU PAS number:
EUPAS1000000966
First published:
30/03/2026
Study
Ongoing
GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND OBSTRUCTIVE SLEEP APNEA RISK USING MEDICARE DATA 2007 - 2019
United States
EU PAS number:
EUPAS1000000965
First published:
30/03/2026
Study
Ongoing
Centre for Maternal, Fetal and Infant Research (MFIR), Ulster University
United Kingdom (Northern Ireland)
First published:
27/03/2026
Institution
Educational Institution
ENCePP partner
Compare data sources
Compare data sources